User:Poisonpearl/Clonal anergy

Article Draft

Lead

Anergy, within the realm of immunology, characterizes the absence of a response from the body's defense mechanisms when confronted with foreign substances. This phenomenon involves the direct induction of peripheral lymphocyte tolerance. When an individual is in a state of anergy, it signifies that their immune system is incapable of mounting a typical response against a specific antigen, typically a self-antigen. The term anergy specifically refers to lymphocytes that exhibit an inability to react to their designated antigen. Notably, anergy constitutes one of the essential processes fostering tolerance within the immune system, alongside clonal deletion and immunoregulation. These processes collectively act to modify the immune response, preventing the inadvertent self-destruction that could result from an overactive immune system.

Mechanism

This phenomenon, first elucidated in B lymphocytes by Gustav Nossal and termed "clonal anergy," highlights a pivotal aspect of immunology. Despite circulating in the bloodstream, these B lymphocyte clones exhibit a profound inability to initiate effective immune responses. Ronald Schwartz and Marc Jenkins expanded upon this concept, identifying a similar process within T lymphocytes, further enriching our understanding of adaptive immunity. Moreover, ongoing research has unveiled the broader implications of clonal anergy in various pathological conditions, particularly in the context of immune evasion by certain viruses like HIV, which exploit tolerance induction mechanisms. This exploitation underscores the sophisticated strategies pathogens employ to evade host defenses. Notably, while many pathogens utilize mechanisms to evade specific immune responses, few exhibit the intricate manipulation of tolerance induction observed, notably Mycobacterium leprae. Understanding the intricate interplay between immune tolerance and evasion mechanisms is paramount in designing effective strategies for immunotherapy and vaccine development, offering potential avenues for therapeutic interventions targeting immune dysregulation in various diseases.

At the cellular level, "anergy" denotes the incapacity of an immune cell to fully engage in a response against its target. Within the immune system, lymphocytes, the circulating cells, constitute the primary defense against pathogenic invaders such as viruses, bacteria and parasites. Two main types of lymphocytes, T lymphocytes, and B lymphocytes, play pivotal roles. Despite the multitude of lymphocytes present in the human body, only a select few are specific to any given infectious agent. Upon infection, these specialized cells must be recruited and allowed to proliferate rapidly through a process known as "clonal expansion." This rapid multiplication enables the swift mobilization of a diverse army of clones, tailored to combat the invading pathogen. This anticipatory immune response is facilitated by pre-existing clones of lymphocytes, which undergo expansion in response to specific antigens, a process termed "clonal selection." This specific clonal army effectively confronts the pathogen until the infection is eradicated. Subsequently, once the infection is cleared, redundant clones naturally under apoptosis. This intricate orchestration highlights the dynamic nature of the immune response, essential for safeguarding the body against infectious threats.

Nevertheless, within the body's extensive array of lymphocytes, a fraction possesses the capacity to react with proteins typically present in a healthy organism. The clonal expansion of these particular cells can precipitate autoimmune diseases, wherein the body erroneously targets its own tissues. To counteract this potentially detrimental process, lymphocytes are equipped with an intrinsic quality-control mechanism. This mechanism effectively suppresses the expansion of lymphocytes if the stimulus for expansion originates from the body's own protein. T-cell anergy can manifest when T-cells fail to receive the necessary co-stimulation in the presence of specific antigen recognition. Similarly, B-cell anergy can be induced through the exposure to soluble circulating antigens, often accompanied by a decrease in surface IgM expression and partial blockade of intracellular signaling pathways. These mechanisms serve as crucial safeguards, preventing the immune system from mounting harmful responses against self-antigens, thereby maintaining immune homeostasis and preventing autoimmune pathology.

Molecular mechanism of anergy induction in T lymphocytes

Understanding the molecular mechanism of anergy induction in T lymphocytes unveils the intricate interplay of signaling pathways governing immune responses. Upon stimulation, the T cell receptor (TCR) in conjunction with costimulatory receptors orchestrates a comprehensive activation of all the T-cell’s signaling pathways, collectively termed full T-cell stimulation. Among these pathways, the calcium-dependent arm of lymphocyte signaling is particularly pivotal, triggered by TCR engagement. This initiates a cascade culminating in an elevation of intracellular Ca^+II concentration, a critical event in T cell activation. Under such conditions, the calcium-dependent phosphatase calcineurin acts on the transcription factor NFAT, facilitating its translocation to the nucleus, where it regulates gene expression.

Expanding upon this complexity, during full T-cell stimulation the co-stimulatory receptor CD28 activates PI3K and other pathways, augmenting the nuclear levels of key transcription factors such as rel, NF-κB and AP-1 beyond those induced by TCR activation alone. The formation of AP-1, fos/jun heterodimer, further complexes with NFAT, creating a transcriptional complex crucial for the expression of genes associated with T-cell productive responses, including IL-2 and its receptor.

In contrast, TCR signaling in the absence of co-stimulatory receptors predominantly activates the calcium arm of the signaling pathway, leading to NFAT activation alone. However, without the concurrent induction of AP-1 by other pathways, NFAT fails to form the transcriptional complex necessary for a productive T-cell response. Instead, NFAT homodimerizes, functioning as a transcriptional factor that induces anergy in the lymphocyte.

NFAT homodimers play a direct role in the expression of anergy-associated genes, such as the ubiquitin ligase GRAIL and the protease caspase 3. Furthermore, anergized cells exhibit decreased expression levels of IL-2, TNFα, and IFNγ, characteristic of a productive response, while favoring the production of the anti-inflammatory cytokine IL-10. Although three NFAT proteins - NFAT1, NFAT2 and NFAT4 - are preset in T-cells, they demonstrate redundancy to some extent.

In the context of antigen presentation by antigen-presenting cells (APC), T lymphocytes undergo a productive response when the antigen is appropriately presented, activating T cell co-stimulatory receptors. However, encountering antigens not presented by the APCs or weakly presented antigens induces anergic responses in T cells. Notably, strong stimulation through IL-2 or TCR/co-stimulatory receptors can overcome anergy, highlighting the dynamic nature of immune regulation.

Moreover, recent research has illuminated the role of regulatory T cells (Tregs) in modulating T cell responses and maintaining immune tolerance. Tregs, characterized by the expression of the transcription factor Foxp3, exert immunosuppressive effects by inhibiting the activation and function of effector T cells. Importantly, Tregs can directly interact with anergic T cells, further reinforcing their state of unresponsiveness and promoting peripheral tolerance. This interaction involves various mechanisms, including the secretion of inhibitory cytokines such as IL-10 and TGF-β, as well as cell-contact-dependent suppression mediated by molecules like CTLA-4. Understanding the intricate crosstalk between Tregs and anergic T cells provides valuable insights into the maintenance of immune homeostasis and has implications for therapeutic strategies aimed at modulating immune responses in autoimmune diseases and transplantation.